Steven Ross, MD
Internal Medicine · Florence, SCNPI 1689647943
Payments from drug & device makers
Across 217 payments — averaging $15.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$483
- Amgen$415
- Merck$237
- AbbVie$221
- Sumitomo Pharma America, Inc.$210
- Esperion Therapeutics, Inc.$187
- plus $2K from 32 others
What the payments were for
- Food & beverage$3,455100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 31 | $483 |
| Amgen | 28 | $415 |
| Merck | 12 | $237 |
| AbbVie(2 entities) | 17 | $221 |
| Sumitomo Pharma America, Inc. | 9 | $210 |
| Esperion Therapeutics, Inc. | 11 | $187 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 11 | $165 |
| Novartis | 10 | $161 |
| Abbott | 10 | $149 |
| Amarin Pharma, Inc. | 10 | $144 |
| Pfizer | 8 | $123 |
| Sanofi-aventis U.S. LLC | 7 | $99 |
| Johnson & Johnson | 6 | $83 |
| GSK | 5 | $83 |
| Eisai Inc. | 5 | $66 |
| Lilly USA, LLC | 4 | $61 |
| Exact Sciences | 3 | $52 |
| Aytu Biopharma, Inc. | 3 | $50 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $40 |
| Radius Health, Inc. | 2 | $38 |
| Cvrx, Inc. | 2 | $38 |
| Boston Scientific | 2 | $37 |
| Dexcom, Inc. | 2 | $37 |
| Astellas Pharma US Inc | 2 | $31 |
| AstraZeneca | 2 | $31 |
| Otsuka America Pharmaceutical, Inc. | 1 | $20 |
| Corcept Therapeutics | 1 | $19 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $19 |
| Bausch Health US, LLC | 1 | $18 |
| Acadia Pharmaceuticals Inc | 1 | $16 |
| Sanofi Pasteur Inc. | 1 | $16 |
| Bayer | 1 | $16 |
| Axsome Therapeutics, Inc. | 1 | $16 |
| Paratek Pharmaceuticals, Inc. | 1 | $15 |
| Xeris Pharmaceuticals, Inc. | 1 | $15 |
| Lundbeck LLC | 1 | $15 |
| Currax Pharmaceuticals LLC | 1 | $14 |
| Shield Therapeutics Inc | 1 | $14 |
How this compares
$3,455 in reported general payments places this provider in the 80th percentile of 1,498 internal medicine providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 306 | $274,435 |
| EliquisApixaban | 171 | $134,628 |
| XareltoRivaroxaban | 106 | $88,180 |
| OzempicSemaglutide | 77 | $77,146 |
| Teriparatide | 23 | $68,663 |
| JanuviaSitagliptin Phosphate | 49 | $61,943 |
| TrulicityDulaglutide | 59 | $61,227 |
| EntrestoSacubitril/Valsartan | 50 | $41,110 |
| RybelsusSemaglutide | 39 | $41,079 |
| MounjaroTirzepatide | 37 | $37,743 |
| FarxigaDapagliflozin Propanediol | 30 | $31,548 |
| Tresiba Flextouch U-200Insulin Degludec | 38 | $29,883 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 94 | $29,062 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 37 | $28,126 |
| LinzessLinaclotide | 30 | $21,585 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Protonix | $123 | $154,470182 claims |
| Novo NordiskOzempic, Rybelsus | $483 | $118,225116 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $61 | $98,97196 claims |
| Johnson & JohnsonXarelto | $83 | $88,180106 claims |
| GSKArexvy, Trelegy Ellipta, Shingrix, Anoro Ellipta | $83 | $72,619184 claims |
| MerckJanuvia, Dulera | $237 | $67,35266 claims |
| NovartisEntresto | $161 | $41,11050 claims |
| AbbVieLinzess, Fetzima, Synthroid | $221 | $32,097117 claims |
| AstraZenecaFarxiga | $31 | $31,54830 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $210 | $13,23428 claims |
| Astellas Pharma US IncMyrbetriq | $31 | $12,32822 claims |
| Esperion Therapeutics, Inc.Nexletol | $187 | $9,90315 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,498 internal medicine providers in South Carolina.
Other internal medicine in Florence
- Rica SantiagoMt Pleasant$10.7M
- Richard MillsMt Pleasant$5.5M
- Yvonne DavisMount Pleasant$2.4M
- David BolsterSummerville$2.3M
- Colby GrossmanSummerville$1.4M
- Amit ShahIndian Land$1.4M
- Philip NicolMurrells Inlet$782K
- Carl SofleyAnderson$673K
- Carl MitchellColumbia$564K
- Jerry BackNorth Charleston$322K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.